When KJ was just seven months old, doctors at the Children's Hospital of Philadelphia gave him an infusion that medical history has never seen before. Unlike every previous gene therapy, which is manufactured once and handed out to many patients, KJ's treatment was custom-made for him alone. It was designed specifically to correct the exact mutation he carried — and it worked.
KJ has citrullinemia type I, a rare inherited disorder caused by a defect in the CPS1 gene. The faulty gene stops the liver from breaking down ammonia, a toxic byproduct of protein. Without intervention, ammonia builds up in the blood and can cause brain damage, seizures, or death. For families with ultra-rare diseases, options are often limited to strict diets and feeding tubes. KJ's team chose a different path: they engineered a one-off CRISPR base-editing therapy that swaps the bad letter in his CPS1 gene for the correct one.
What makes the case remarkable is the speed. From diagnosis to treatment, the entire bespoke therapy was developed and manufactured in roughly six months. The clinical results were encouraging — KJ began tolerating more dietary protein and the need for an intravenous feeding line was reduced. Base editors are a refinement of the CRISPR system: rather than cutting DNA, they change one chemical letter into another with far fewer unwanted edits, which matters enormously when the target is a single patient.
The broader significance is that KJ proves a "personalized" model of gene editing is medically feasible. Most people carrying a given rare mutation would still receive an off-the-shelf therapy — but KJ's case demonstrates that a bespoke edit can be designed, built and delivered fast enough to matter in a real patient. Doctors now see it as the first step toward personalized editing for other rare conditions, pending regulatory approval.
Knowledge takeaway: Baby KJ was the first person of any age to receive a bespoke, patient-specific CRISPR base-editing therapy for a rare metabolic disorder (CPS1 deficiency); the custom treatment was developed in about six months and let him tolerate more dietary protein; the case demonstrates that truly personalized gene editing is technically and logistically possible.